Ivan Vilotijevic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivan Vilotijevic has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
You Zi
Institute for Organic Chemistry and Macromolecular Chemistry Friedrich Schiller University Jena Humboldtstrasse 10 07743 Jena Germany
12 shared publicationsMarkus Lange
Friedrich Schiller University Jena
11 shared publications- Daniel Varón Silva
Max Planck Institute of Colloids and Interfaces, Potsdam, Germany and Freie Universität Berlin
7 shared publications Fritz Schömberg
Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Humboldtstraße 10, 07743 Jena, Germany
7 shared publicationsJiong Yang
Evans Chem. Lab., Ohio State Univ., Columbus, OH 43210, USA
6 shared publicationsDenis Drikermann
Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, 07743 Jena, Germany
5 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (38) , 13061-13067
Accessing Sterically Congested Benzannulated Cyclic Aryl Ethers via Photoredox Decarboxylative Giese-Type C2–C3 Bond Formation
The visible-light-driven photocatalytic decarboxylation of α-aryloxy carboxylic acids produces α-oxy carbon-centered radicals that undergo intramolecular Giese addition to form 2,3-dihydrobenzofurans, chromans, 2,3,4,5-tetrahydrobenzo[b]oxepines, and 3,4,5,6-tetrahydro-2H-benzo[b]oxocines. In contrast to the existing methods, this unconventional strategy for the construction of five-, six-, seven-, and eight-membered oxygen heterocycles via the formation of the C2–C3 bond enables the synthesis of sterically demanding O-heterocycles bearing multiple substituents at the C2 and C3 positions. The mild reaction conditions render these transformations highly chemoselective and compatible with various functional groups.
- 16 September 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (38) , 13061-13067
Open AccessAccessing Sterically Congested Benzannulated Cyclic Aryl Ethers via Photoredox Decarboxylative Giese-Type C2–C3 Bond Formation
The visible-light-driven photocatalytic decarboxylation of α-aryloxy carboxylic acids produces α-oxy carbon-centered radicals that undergo intramolecular Giese addition to form 2,3-dihydrobenzofurans, chromans, 2,3,4,5-tetrahydrobenzo[b]oxepines, and 3,4,5,6-tetrahydro-2H-benzo[b]oxocines. In contrast to the existing methods, this unconventional strategy for the construction of five-, six-, seven-, and eight-membered oxygen heterocycles via the formation of the C2–C3 bond enables the synthesis of sterically demanding O-heterocycles bearing multiple substituents at the C2 and C3 positions. The mild reaction conditions render these transformations highly chemoselective and compatible with various functional groups.
- Open Access
- 9 September 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (43) , e9880949
Adenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic
Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.
- 9 September 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (43) , e9880949
Open AccessAdenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic
Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.
- Open Access
- 9 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (43)
Adenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic
Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.
- 9 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (43)
Open AccessAdenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic
Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.
- Open Access
- 16 May 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (8) , 1344-1366
Recent insights into the biosynthesis and biological activities of the peptide-derived redox cofactor mycofactocin
Covering: 2011 to 2025 The importance of redox cofactors like nicotinamide adenine dinucleotide or flavin adenine dinucleotide as cofactors for enzymatic reactions in living organisms is widely known. However, many microbial species also employ unusual redox cofactors such as the coenzyme F420 or the peptide-derived pyrroloquinoline quinone (PQQ). In this review, we introduce the reader to the recently discovered bacterial redox cofactor mycofactocin (MFT), a valine-tyrosine-derived small molecule of the class of ribosomally synthesized and post-translationally modified peptides (RiPPs) with remarkable biosynthetic and functional similarities to PQQ. The cofactor plays an important role in the reoxidation of non-exchangeable nicotinamide redox cofactors of specialized oxidoreductases in mycobacteria and related actinobacteria. We highlight the bioinformatic discovery of the mycofactocin gene cluster and its auxiliary genes, present strategies for the chemical synthesis of the cofactor, and take a detailed look at the biosynthesis of the glycosylated molecule. Subsequently, the diverse mycofactocin-inducing conditions and associated oxidoreductase families are reviewed, and a potential electron transfer route from high-energy alcohols via mycofactocin to oxygen as a final electron acceptor is presented. The review concludes with a comparison of the physiological roles of PQQ and MFT, and an outlook for future research questions and potential biotechnological applications of mycofactocin.
- 16 May 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (8) , 1344-1366
Open AccessRecent insights into the biosynthesis and biological activities of the peptide-derived redox cofactor mycofactocin
Covering: 2011 to 2025 The importance of redox cofactors like nicotinamide adenine dinucleotide or flavin adenine dinucleotide as cofactors for enzymatic reactions in living organisms is widely known. However, many microbial species also employ unusual redox cofactors such as the coenzyme F420 or the peptide-derived pyrroloquinoline quinone (PQQ). In this review, we introduce the reader to the recently discovered bacterial redox cofactor mycofactocin (MFT), a valine-tyrosine-derived small molecule of the class of ribosomally synthesized and post-translationally modified peptides (RiPPs) with remarkable biosynthetic and functional similarities to PQQ. The cofactor plays an important role in the reoxidation of non-exchangeable nicotinamide redox cofactors of specialized oxidoreductases in mycobacteria and related actinobacteria. We highlight the bioinformatic discovery of the mycofactocin gene cluster and its auxiliary genes, present strategies for the chemical synthesis of the cofactor, and take a detailed look at the biosynthesis of the glycosylated molecule. Subsequently, the diverse mycofactocin-inducing conditions and associated oxidoreductase families are reviewed, and a potential electron transfer route from high-energy alcohols via mycofactocin to oxygen as a final electron acceptor is presented. The review concludes with a comparison of the physiological roles of PQQ and MFT, and an outlook for future research questions and potential biotechnological applications of mycofactocin.
- Open Access
- 29 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4235
Anti-Influenza Activity of 6BIGOE: Improved Pharmacological Profile After Encapsulation in PLGA Nanoparticles
Influenza A virus (IAV) infections continue to threaten public health. Current strategies, such as vaccines and antiviral drugs, are limited due to their time-consuming development and drug-resistant strains. Therefore, new effective treatments are needed. Here, virus-supportive cellular factors are promising drug targets, and the encapsulation of candidate substances in poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) is intended to improve their bioavailability. This study investigates the potential of the indirubin derivative 6-bromoindirubin-3′-glycerol-oxime ether (6BIGOE), a glycogen synthase kinase 3 (GSK-3)β inhibitor, for its potential to regulate IAV replication in vitro. The effects of 6BIGOE-loaded PLGA NPs on cell metabolism were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays in A549 and Calu-3 cells. Viral replication and spread were monitored in various IAV-infected cell lines in the absence and presence of free and 6BIGOE-loaded PLGA NPs via plaque assays and Western blot analysis. The encapsulation of 6BIGOE in PLGA NPs resulted in reduced negative side effects on cell viability while maintaining antiviral efficacy. Both encapsulated and free 6BIGOE exhibited antiviral activity, potentially through GSK-3β inhibition and the disruption of key signaling pathways required for viral replication. The data indicate 6BIGOE, particularly after encapsulation in NPs, as a potential candidate for further investigation and development as an antiviral agent to treat IAV infections.
- 29 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4235
Open AccessAnti-Influenza Activity of 6BIGOE: Improved Pharmacological Profile After Encapsulation in PLGA Nanoparticles
Influenza A virus (IAV) infections continue to threaten public health. Current strategies, such as vaccines and antiviral drugs, are limited due to their time-consuming development and drug-resistant strains. Therefore, new effective treatments are needed. Here, virus-supportive cellular factors are promising drug targets, and the encapsulation of candidate substances in poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) is intended to improve their bioavailability. This study investigates the potential of the indirubin derivative 6-bromoindirubin-3′-glycerol-oxime ether (6BIGOE), a glycogen synthase kinase 3 (GSK-3)β inhibitor, for its potential to regulate IAV replication in vitro. The effects of 6BIGOE-loaded PLGA NPs on cell metabolism were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays in A549 and Calu-3 cells. Viral replication and spread were monitored in various IAV-infected cell lines in the absence and presence of free and 6BIGOE-loaded PLGA NPs via plaque assays and Western blot analysis. The encapsulation of 6BIGOE in PLGA NPs resulted in reduced negative side effects on cell viability while maintaining antiviral efficacy. Both encapsulated and free 6BIGOE exhibited antiviral activity, potentially through GSK-3β inhibition and the disruption of key signaling pathways required for viral replication. The data indicate 6BIGOE, particularly after encapsulation in NPs, as a potential candidate for further investigation and development as an antiviral agent to treat IAV infections.
- Open Access
- 19 March 2025
- Published by MDPI AG in Preprints.org
Anti-Influenza Activity of 6BIGOE: Improved Pharmacological Profile After Encapsulation in Plga Nanoparticles
Influenza A virus (IAV) infections continue to threaten public health. Current strategies, such as vaccines and antiviral drugs, are limited due to time-consuming development and drug-resistant strains. Therefore, new effective treatments are needed. Here, virus-supportive cellular factors are promising drug targets, and encapsulation of candidate substances in PLGA nanoparticles (NPs) is intended to improve their bioavailability. This study investigates the potential of the indirubin derivative 6BIGOE, a GSK-3β inhibitor, for its potential to regulate IAV replication in vitro. The effects of 6BIGOE-loaded PLGA NPs on cell metabolism were assessed by MTT and LDH assays in A549 and Calu-3 cells. Viral replication and spread were monitored in various IAV-infected cell lines in absence and presence of free and 6BIGOE-loaded PLGA NPs via plaque assays and Western blot analysis. Encapsulation of 6BIGOE in PLGA NPs resulted in reduced negative side effects on cell viability while maintaining antiviral efficacy. Both encapsulated and free 6BIGOE exhibited antiviral activity, potentially through GSK-3β inhibition and disruption of key signaling pathways required for viral replication. The data indicate 6BIGOE, particularly after encapsulation in NPs, as a potential candidate for further investigation and development as an antiviral agent to treat IAV infections.
- 19 March 2025
- Published by MDPI AG in Preprints.org
Open AccessAnti-Influenza Activity of 6BIGOE: Improved Pharmacological Profile After Encapsulation in Plga Nanoparticles
Influenza A virus (IAV) infections continue to threaten public health. Current strategies, such as vaccines and antiviral drugs, are limited due to time-consuming development and drug-resistant strains. Therefore, new effective treatments are needed. Here, virus-supportive cellular factors are promising drug targets, and encapsulation of candidate substances in PLGA nanoparticles (NPs) is intended to improve their bioavailability. This study investigates the potential of the indirubin derivative 6BIGOE, a GSK-3β inhibitor, for its potential to regulate IAV replication in vitro. The effects of 6BIGOE-loaded PLGA NPs on cell metabolism were assessed by MTT and LDH assays in A549 and Calu-3 cells. Viral replication and spread were monitored in various IAV-infected cell lines in absence and presence of free and 6BIGOE-loaded PLGA NPs via plaque assays and Western blot analysis. Encapsulation of 6BIGOE in PLGA NPs resulted in reduced negative side effects on cell viability while maintaining antiviral efficacy. Both encapsulated and free 6BIGOE exhibited antiviral activity, potentially through GSK-3β inhibition and disruption of key signaling pathways required for viral replication. The data indicate 6BIGOE, particularly after encapsulation in NPs, as a potential candidate for further investigation and development as an antiviral agent to treat IAV infections.
- 22 October 2024
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 36 (07) , 879-883
Silyl Ethers as Latent Pronucleophiles in Enantioselective Lewis Base Catalyzed Synthesis of Allylic Ethers from Allylic Fluorides
Allylic ethers are a common occurrence in natural products, and are often used as intermediates in target-oriented synthesis. Their synthesis often relies on the use of transition-metal catalysts. Here, we report an organocatalytic method for the allylation of O-centered nucleophiles, the Lewis base catalyzed allylation of silyl ethers with allylic fluorides. The method relies on the concept of latent pronucleophiles in Lewis base catalysis to overcome common limitations in substrate scope, even permitting the allylation of sterically congested O-pronucleophiles. When chiral Lewis base catalysts are used, the allyl ethers are produced in an enantioenriched form through kinetic resolution of fluorides, where the stereoselectivity is determined by the chiral catalyst.
- 22 October 2024
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 36 (07) , 879-883
Silyl Ethers as Latent Pronucleophiles in Enantioselective Lewis Base Catalyzed Synthesis of Allylic Ethers from Allylic Fluorides
Allylic ethers are a common occurrence in natural products, and are often used as intermediates in target-oriented synthesis. Their synthesis often relies on the use of transition-metal catalysts. Here, we report an organocatalytic method for the allylation of O-centered nucleophiles, the Lewis base catalyzed allylation of silyl ethers with allylic fluorides. The method relies on the concept of latent pronucleophiles in Lewis base catalysis to overcome common limitations in substrate scope, even permitting the allylation of sterically congested O-pronucleophiles. When chiral Lewis base catalysts are used, the allyl ethers are produced in an enantioenriched form through kinetic resolution of fluorides, where the stereoselectivity is determined by the chiral catalyst.
- Open Access
- 3 August 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (33) , 6684-6689
Enantioselective Lewis base catalysed allylation of picoline- and quinaldine-based latent pronucleophiles
The concept of latent pronucleophiles enables selective allylation of picolines and quinaldines with allylic fluorides in the presence of Lewis base catalysts. The products are isolated as single regioisomers with good yields and enantioselectivity.
- 3 August 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (33) , 6684-6689
Open AccessEnantioselective Lewis base catalysed allylation of picoline- and quinaldine-based latent pronucleophiles
The concept of latent pronucleophiles enables selective allylation of picolines and quinaldines with allylic fluorides in the presence of Lewis base catalysts. The products are isolated as single regioisomers with good yields and enantioselectivity.
- Open Access
- 6 July 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-8
Modulation of the Meisenheimer complex metabolism of nitro-benzothiazinones by targeted C-6 substitution
Tuberculosis, caused by Mycobacterium tuberculosis, remains a major public health concern, demanding new antibiotics with innovative therapeutic principles due to the emergence of resistant strains. Benzothiazinones (BTZs) have been developed to address this problem. However, an unprecedented in vivo biotransformation of BTZs to hydride-Meisenheimer complexes has recently been discovered. Herein, we present a study of the influence of electron-withdrawing groups on the propensity of HMC formation in whole cells for a series of C-6-substituted BTZs obtained through reductive fluorocarbonylation as a late-stage functionalization key step. Gibbs free energy of reaction and Mulliken charges and Fukui indices on C-5 at quantum mechanics level were found as good indicators of in vitro HMC formation propensity. These results provide a first blueprint for the evaluation of HMC formation in drug development and set the stage for rational pharmacokinetic optimization of BTZs and similar drug candidates.
- 6 July 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-8
Open AccessModulation of the Meisenheimer complex metabolism of nitro-benzothiazinones by targeted C-6 substitution
Tuberculosis, caused by Mycobacterium tuberculosis, remains a major public health concern, demanding new antibiotics with innovative therapeutic principles due to the emergence of resistant strains. Benzothiazinones (BTZs) have been developed to address this problem. However, an unprecedented in vivo biotransformation of BTZs to hydride-Meisenheimer complexes has recently been discovered. Herein, we present a study of the influence of electron-withdrawing groups on the propensity of HMC formation in whole cells for a series of C-6-substituted BTZs obtained through reductive fluorocarbonylation as a late-stage functionalization key step. Gibbs free energy of reaction and Mulliken charges and Fukui indices on C-5 at quantum mechanics level were found as good indicators of in vitro HMC formation propensity. These results provide a first blueprint for the evaluation of HMC formation in drug development and set the stage for rational pharmacokinetic optimization of BTZs and similar drug candidates.
- Open Access
- 22 May 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 149, 107470
Bromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes
- 22 May 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 149, 107470
Open AccessBromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes